Inhibikase Therapeutics will submit an IND application for Ikt-001Pro for the treatment of pulmonary arterial hypertension to the FDA in early Q3.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.